Cited 0 times in Scipus Cited Count

Comparison of the clinical efficacy of NBUVB and NBUVB with benzoyl peroxide/clindamycin in progressive macular hypomelanosis.

DC Field Value Language
dc.contributor.authorSim, JH-
dc.contributor.authorLee, DJ-
dc.contributor.authorLee, JS-
dc.contributor.authorKim, YC-
dc.date.accessioned2012-05-09T01:20:46Z-
dc.date.available2012-05-09T01:20:46Z-
dc.date.issued2011-
dc.identifier.issn0926-9959-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/6867-
dc.description.abstractBACKGROUND: Progressive macular hypomelanosis (PMH) is a skin disorder characterized by multiple hypopigmented patches symmetrically distributed on the trunk. Several treatment modalities have been attempted; however, a standard treatment modality has not been agreed to.



OBJECTIVES: The aim of this study was to compare the effectiveness of antimicrobial therapy combined with narrow band ultraviolet B (NBUVB) with NBUVB monotherapy.



METHODS: A randomized left-right comparison study was conducted in a total of 10 patients. Patients received NBUVB therapy with daily application of antimicrobial gel on one side of the trunk (comb-NBUVB) and without it (mono-NBUVB) for 8 weeks. The clinical efficacy was determined by objective measurements using a colour analyser and subjective assessment by evaluating pictures taken with a digital camera at baseline, at the time of treatment cessation and 6 months after treatment.



RESULTS: Significant repigmentation was observed in all 10 patients during the 8 weeks of treatment. The mean difference in L values between lesional and non-lesional skin was reduced in the comb-NBUVB area (from 4.52 ± 1.65 to 0.94 ± 0.65), and in the mono-NBUVB area, (from 4.34 ± 1.39 to 1.18 ± 0.94). There was no significant difference between treated sites at both of the evaluation points in time. At 6 months after treatment, 7 of 10 patients completed the clinical trial, and some degree of clinical improvement remained in four of seven patients; recurrence occurred in the other patients.



CONCLUSIONS: Although recurrence occurred in some patients, NBUVB treatment appears to be a safe and useful modality for the treatment of PMH.
-
dc.language.isoen-
dc.subject.MESHBenzoyl Peroxide-
dc.subject.MESHClindamycin-
dc.subject.MESHHumans-
dc.subject.MESHPhotochemotherapy-
dc.titleComparison of the clinical efficacy of NBUVB and NBUVB with benzoyl peroxide/clindamycin in progressive macular hypomelanosis.-
dc.typeArticle-
dc.identifier.pmid21349111-
dc.contributor.affiliatedAuthor김, 유찬-
dc.type.localJournal Papers-
dc.identifier.doi10.1111/j.1468-3083.2011.03980.x-
dc.citation.titleJournal of the European Academy of Dermatology and Venereology : JEADV-
dc.citation.volume25-
dc.citation.number11-
dc.citation.date2011-
dc.citation.startPage1318-
dc.citation.endPage1323-
dc.identifier.bibliographicCitationJournal of the European Academy of Dermatology and Venereology : JEADV, 25(11). : 1318-1323, 2011-
dc.identifier.eissn1468-3083-
dc.relation.journalidJ009269959-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Dermatology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse